MML Investors Services LLC Has $11.64 Million Stake in Sanofi (NASDAQ:SNY)

MML Investors Services LLC boosted its holdings in Sanofi (NASDAQ:SNY - Free Report) by 4.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 241,401 shares of the company's stock after acquiring an additional 10,865 shares during the quarter. MML Investors Services LLC's holdings in Sanofi were worth $11,643,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. State Street Corp grew its holdings in shares of Sanofi by 0.5% in the 3rd quarter. State Street Corp now owns 56,734 shares of the company's stock worth $3,270,000 after purchasing an additional 264 shares during the last quarter. Barclays PLC increased its holdings in shares of Sanofi by 107.5% during the third quarter. Barclays PLC now owns 639,772 shares of the company's stock worth $36,869,000 after buying an additional 331,445 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Sanofi by 7.1% in the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company's stock valued at $14,681,000 after acquiring an additional 16,780 shares during the last quarter. World Investment Advisors LLC boosted its holdings in shares of Sanofi by 1,020.5% in the 3rd quarter. World Investment Advisors LLC now owns 48,430 shares of the company's stock worth $2,791,000 after acquiring an additional 44,108 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Sanofi during the 3rd quarter valued at $219,000. Institutional investors and hedge funds own 14.04% of the company's stock.

Sanofi Stock Up 1.4 %

Shares of NASDAQ:SNY traded up $0.75 during mid-day trading on Monday, reaching $53.07. 536,409 shares of the stock were exchanged, compared to its average volume of 2,358,242. The company has a market cap of $134.07 billion, a P/E ratio of 21.31, a P/E/G ratio of 1.01 and a beta of 0.57. The stock's 50 day simple moving average is $54.53 and its 200-day simple moving average is $52.05. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a one year low of $45.80 and a one year high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The firm had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. As a group, equities research analysts predict that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be given a $2.0369 dividend. This represents a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, May 9th. This is an increase from Sanofi's previous annual dividend of $1.48. Sanofi's dividend payout ratio (DPR) is 57.14%.

Analyst Ratings Changes

Several brokerages have recently commented on SNY. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. The Goldman Sachs Group initiated coverage on Sanofi in a report on Friday, March 21st. They set a "neutral" rating and a $65.00 price objective for the company. BNP Paribas assumed coverage on shares of Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price target for the company. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Three analysts have rated the stock with a hold rating, two have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $63.33.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.